The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Stock and Other Ownership Interests - ECOM Medical
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; EMD Serono; Exelixis; Genentech; Novartis; Pfizer
Speakers' Bureau - Amgen; Astellas Medivation; AstraZeneca; Bristol-Myers Squibb; Eisai; EMD Serono; Exelixis; Genentech/Roche; Janssen; Merck; Novartis; Pfizer; Sanofi
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Bavarian Nordic (Inst); Bayer (Inst); BeyondSpring Pharmaceuticals (Inst); BioClin Therapeutics (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Eisai (Inst); Epizyme (Inst); Exelixis (Inst); Genentech (Inst); Immunomedics (Inst); Janssen (Inst); Macrogenics (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - Astellas Medivation; AstraZeneca; Bayer; Eisai; Exelixis; Genentech; Janssen; Novartis; Pfizer; Prometheus
Phase Ib/II umbrella trial to evaluate the safety and efficacy of multiple 2L cancer immunotherapy (CIT) combinations in advanced/metastatic urothelial carcinoma (mUC): MORPHEUS-mUC.
 
Alexandra Drakaki
Employment - Kyn therapeutics (I)
Leadership - Kyn therapeutics (I)
Stock and Other Ownership Interests - Alimera Sciences (I); Athos Therapeutics (I); Kyn therapeutics (I); Urogen pharma (I)
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Kyn therapeutics; RADMETRIX; Seagen
Research Funding - Kite/Gilead
Patents, Royalties, Other Intellectual Property - My significant other has 5 patents with UCLA. (I)
Travel, Accommodations, Expenses - AstraZeneca; Lilly; Seagen
 
Arash Rezazadeh Kalebasty
No Relationships to Disclose
 
Jae-Lyun Lee
Honoraria - Amgen; Astellas Pharma; Bristol-Myers Squibb; Pfizer
Consulting or Advisory Role - Alteogen; Bristol-Myers Squibb; Pfizer; Sanofi/Aventis
Research Funding - AstraZeneca/MedImmune (Inst); Bayer Schering Pharma (Inst); Bristol-Myers Squibb (Inst); Janssen (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst); Seagen (Inst)
 
Juan Martin-Liberal
Consulting or Advisory Role - Bristol-Myers Squibb; Novartis; Pierre Fabre; Roche
Speakers' Bureau - Astellas Pharma; Bristol-Myers Squibb; MSD; Novartis; Pfizer; Pierre Fabre; Roche
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Ipsen; MSD; Novartis; Pfizer; Pierre Fabre; Roche
 
Miso Kim
Consulting or Advisory Role - AstraZeneca; Ipsen
 
Sang Joon Shin
No Relationships to Disclose
 
Jane Shi
No Relationships to Disclose
 
Sanjeev Mariathasan
Employment - Roche/Genentech
Stock and Other Ownership Interests - Roche/Genentech
Patents, Royalties, Other Intellectual Property - US8217149- Patent describing Atezolizumab invention :
 
Bo Ci
Employment - Genentech
 
Viraj Degaonkar
Employment - Roche/Genentech
Stock and Other Ownership Interests - Roche/Genentech
 
Patrick Williams
Employment - Genentech
Stock and Other Ownership Interests - Genentech/Roche
Travel, Accommodations, Expenses - Genentech
 
Edward Cha
Employment - Genentech/Roche
Stock and Other Ownership Interests - Genentech/Roche
 
Julia Maltzman
Employment - Roche/Genentech
Stock and Other Ownership Interests - Roche/Genentech
Consulting or Advisory Role - Roche/Genentech
Travel, Accommodations, Expenses - Roche/Genentech
Other Relationship - Roche/Genentech
 
Thomas Powles
Honoraria - AstraZeneca; Bristol-Myers Squibb; Ferring; Gerson Lehrman Group; Janssen Research & Development; MERCK; Novartis; Pfizer; Roche/Genentech; Seattle Genetics/Astellas
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Genentech/Roche; Incyte; Ipsen; Merck; Novartis; Novartis; Pfizer; Seagen
Research Funding - AstraZeneca/MedImmune; Roche/Genentech
Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb; Ferring; MSD; Novartis/Ipsen; Pfizer; Research to Practice; Roche/Genentech